NIKKEI 225
28,147.51-461.08(-1.61%)HANG SENG
28,231.04+217.23(+0.78%)CRUDE OIL
63.78-2.30(-3.48%)
MEDICLIN Aktiengesellschaft (0NDG.L)
| Previous close | 5.25 |
| Open | 5.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.25 - 5.25 |
| 52-week range | 5.25 - 5.25 |
| Volume | 5,000 |
| Avg. volume | N/A |
| Market cap | 243.576M |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.33 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
MediClin AG: The effects of the coronavirus pandemic are burdening the business development in the first quarter of 2021
DGAP-News: MediClin AG / Key word(s): Quarterly / Interim Statement03.05.2021 / 17:58 The issuer is solely responsible for the content of this announcement.The effects of the coronavirus pandemic are burdening the business development in the first quarter of 2021The economic and social effects of the coronavirus pandemic, i.e. lockdown, increasing capacity utilization in intensive care units, reserved capacities and postponed acute treatments, weighed on the business development of MEDICLIN Aktiengesellschaft (MEDICLIN) in the first quarter of the new financial year 2021.Group EBIT significantly below prior-year quarter despite cost reductions lIn the 1st quarter of 2021, Group sales amounted to EUR 156.4 mill. and were EUR 11.0 mill. or 6.6% below the value of the 1st quarter of 2020. Group sales include a total of EUR 7.6 mill. in protective shielding benefits for free capacities and payments on the part of the cost providers for additional expenses for hygiene and protective materials.Despite these benefits and a total of EUR 2.1 mill. lower expenses, the Group operating result was EUR -11.9 mill. and thus EUR 8.0 mill. below the value of the first quarter of 2020. Protective shield benefits and payments from the cost providers, which have been severely reduced by politicians, only accounted for a small part of the capacity losses and the higher costs", said Tino Fritz, CFO of MEDICLIN, commenting on the business development.Cash and cash equivalents as of 31 March 2021 amounted to EUR 100.1 mill. (31.12.2020: EUR 100.4 mill.). Cash and cash equivalents contain a total of about EUR 56.0 mill. in expected repayments to be made in the course of 2021, in particular of benefits under the protective shield previously received. Furthermore, the cash and cash equivalents item includes about EUR 18.0 mill. in subsidies for the planned construction of a new clinic.OutlookThe number of people infected with corona, which has been rising steadily since the beginning of February 2021, and the capacity bottlenecks in clinics with intensive care units, only allow a reliable estimate on the company's own business development based on experience gained in the previous year. "The sales and earnings development for the year as a whole depends largely on the development of the pandemic and the protective shielding benefits, which will be significantly lower in 2021 than in the previous year," said Volker Hippler, CEO of MEDICLIN.Currently, MEDICLIN assumes that occupancy rates at pre-Corona levels will not be achievable before the second half of the year 2021 as vaccinations are progressing only very slowly.The interim report for the first quarter of 2021 is available from today at https://www.mediclin.de/investor-relations/finanzpublikationen/ in German and English./About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.MEDICLIN ─ ein Unternehmen der Asklepios-Gruppe.03.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1191921 End of News DGAP News Service
- EQS Group
MediClin AG: MEDICLIN has achieved the revised targets for 2020
DGAP-News: MediClin AG / Key word(s): Preliminary Results26.02.2021 / 14:15 The issuer is solely responsible for the content of this announcement.Offenburg, February 26, 2021MEDICLIN has achieved the revised targets for 2020 In the 2020 financial year, Group sales of MEDICLIN Aktiengesellschaft (MEDICLIN) of EUR 659.9 mill. were EUR 13.2 mill. or 2.0% below the previous year's value. The preliminary Group operating result is EUR 0.2 mill. (previous year: EUR 22.4 mill.).Targets achieved despite the start of the 2nd wave of the pandemic at the end of the yearIn April 2020, the original forecast for the 2020 financial year had to be withdrawn due to the corona pandemic, MEDICLIN published an outlook for 2020 at the beginning of November 2020. A continued positive development in patient intake with a stable infection rate was assumed. A decrease in sales in the Group of 2.0% and a Group operating result in the amount of the breakeven point were anticipated.The effects of the pandemic have left their mark on business development The effects of the corona pandemic left their mark on MEDICLIN's business development in 2020, despite the state protective shield and subsidies from the cost providers. In the first half of 2020 in particular, capacities were kept free for corona patients in both the acute clinics and the rehabilitation clinics. A slow ramp-up of capacities to normal operation under strict hygiene regulations allowed the capacity utilization to rise again somewhat in the second half of the year. At the end of the year, the strongly increasing number of infected people and the general reluctance of the population to undergo acute treatment in the current situation had a dampening effect on the occupancy rate in the rehabilitation clinics.Fewer patients in the post-acute segment - Nursing segment stableIn the post-acute segment, sales fell by EUR 23.0 mill. or 5.5% to EUR 393.7 mill. (previous year: EUR 416.7 mill.). The preliminary segment result is EUR 4.8 mill. (previous year: EUR 23.1 mill.).In the acute segment, sales of EUR 248.7 mill. were EUR 12.1 mill. or 5.1% above the previous year's figure (previous year: EUR 236.6 mill.). The preliminary segment result is EUR -1.5 mill. (previous year: EUR 1.6 mill.). The segment result is burdened by a one-off effect of EUR 1.4 mill. from a book value depreciation resulting from the sale of MediClin Krankenhaus am Crivitzer See GmbH, Crivitz, as of December 31, 2020.The nursing care business area generated sales of EUR 15.8 mill. (previous year: EUR 15.3 mill.).The number of staff rose slightly in 2020The average number of full-time employees in 2020 was 7,471 full-time employees (previous year: 7,431 full-time employees). The number of trainees in the reporting year amounted to an average of 361 trainees (previous year: 328 trainees).Sound financial structureIn the 2020 financial year, EUR 26.6 mill. (previous year: EUR 48.2 mill.) was invested in non-current assets (gross amount). A total of EUR 16.1 mill. (previous year: EUR 17.5 mill.) was spent on maintenance and repair. At the end of the year, liquid funds were above the previous year's value, mainly due to cost-cutting measures, deferred investment projects and liquidity inflows within the framework of the protective shield.The equity ratio as of the balance sheet date was 19.9% (December 31, 2020: 21.2%).The 2020 annual report will be available in German and English from March 26, 2021 at https://www.mediclin.de/investor-relations/finanzpublikationen/./ About MEDICLIN AG (Ticker: MED; WKN: 659 510)MEDICLIN owns 35 clinics, seven nursing care facilities and ten medical care centres. The Group has about 8,350 beds/places and a headcount of about 10,300. With its strong network, MEDICLIN can offer its patients integrated care from the first visit to the doctor to surgery, post-operative rehabilitation and follow-up care at home. Doctors, therapists and nurses work together closely to achieve the best results. MEDICLIN plans the care of persons in need in accordance with their individual requirements and personal needs.MEDICLIN - A company of the Asklepios Group.26.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1171594 End of News DGAP News Service
- EQS Group
MediClin AG: The Board of Management of MEDICLIN will be expanded - Dr. York Dhein will join on April 1st, 2021
DGAP-News: MediClin AG / Key word(s): Personnel12.01.2021 / 14:00 The issuer is solely responsible for the content of this announcement.Offenburg, January 12, 2021The Board of Management of MEDICLIN will be expanded - Dr. York Dhein will join on April 1st, 2021In its meeting on January 11, 2021, the Supervisory Board of MEDICLIN Aktiengesellschaft appointed Dr. med. York Dhein as additional member to the Management Board of MEDICLIN AG.The 54-year-old is a specialist in internal medicine and, after working in a clinic, worked for a large company health insurance fund for several years, last as head of care and contract management. This was followed by five years as a consultant in the health care business of an international management consulting company. Since 2013 he has been a member of the board and later chairman of the board of Johannesbad Holding SE & Co. KG, a family-run group of companies with a clear profile as a health service provider with a focus on rehabilitation.York Dhein stands up for a stronger position of rehabilitation in the health sector for years. He has an excellent branch network and is involved in the board of the VPKA (Association of Private Hospitals) Bavaria.The Management Board welcomes the reinforcement in the top management of MEDICLIN. The demands on the health system will increase significantly in the future, and with it the challenges in the largest segment of MEDICLIN, the post-acute segment.About MEDICLIN AG (Ticker: MED; WKN: 659 510)MEDICLIN has around 8,500 beds / care places and employs about 10,500 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and the subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual and personal needs.MEDICLIN - A company of the Asklepios Group.12.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1160059 End of News DGAP News Service
